Table 1 Characteristics of the included studies
Author | Year | Patients’ diagnosis | Surgery | Study design | Enrolled sample number (M/F) | Average age, years | Outcome measurement | Quality assessment |
|---|---|---|---|---|---|---|---|---|
Gillespie [20] | 2015 | OA | TSA 44 RTSA 67 | Randomized controlled trial | TXA 56 (27/29) Placebo 55 (22/33) | TXA: 67.59 Placebo:66.45 | Blood loss via drainage, Hb change, ETBL, transfusions, complications | Detail shown in Fig. 2 |
Pauzenberger [20] | 2017 | Not mentioned | TSA 26 RTSA 28 | Randomized controlled trial | TXA 27(20/7) Placebo 27(18/9) | TXA: 70.3 ± 9.3 Placebo:71.3 ± 7.9 | Blood loss via drainage, Hb/Hct change, ETBL, haematoma, complications | Detail shown in Fig. 2 |
Vara [34] | 2017 | Massive rotator cuff deficiency ± glenohumeral arthrosis | RTSA 102 | Randomized controlled trial | TXA 53(20/33) Placebo 49(22/27) | TXA: 67 ± 9 Placebo:66 ± 9 | Blood loss via drainage, Hb change, ETBL, operation time, hospital stay, transfusions, complications | Detail shown in Fig. 2 |
Abildgaard [33] | 2016 | TSA:1 ON and 7 OA RTSA:45 CTA, 34 massive cuff tear, 1 ON, 1RA, 11OA, and 2 fractures | TSA 77 RTSA 94 | Retrospective cohort study | TXA 77 (49/28) Placebo 94 (51/43) | TSA: TXA: 70 (53–87) Placebo:71 (58–87) RTSA TXA: 74 (54–90) Placebo: 76(54–89) | Blood loss via drainage, Hb/Hct change, ETBL, transfusions, complications | 9a |
Friedman [19] | 2016 | Not mentioned | TSA 97 RTSA 97 | Retrospective cohort study | TXA 106 (46/60) Placebo 88 (33/55) | not mentioned | Hb/Hct, recover room time, operation time, hospital stay, transfusions, complications | 8a |
Kim [24] | 2017 | CTA | RTSA 48 | Retrospective cohort study | TXA 24 (3/21) Placebo 24 (6/18) | TXA: 73.2 ± 4.4 Placebo: 74.2 ± 4.4 | Hb/Hct change, operation time, blood loss via drainage | 8a |